Epigenetic biomarkers in laboratory diagnostics: Emerging approaches and opportunities

Expert Review of Molecular Diagnostics

Volumn 13, Issue 5, 2013, Pages 457-471

  Sandoval, Juan ^a   Peiró Chova, Lorena ^b   Pallardó, Federico V ^b,c,d   Garcia Gimenez J L ^b,c,d  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b Instituto Universitario IVI INCLIVA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

cancer; DNA methylation; epigenetics; histones; miRNA; rare diseases

Indexed keywords

DNA; HISTONE; MICRORNA; TUMOR MARKER;

CLINICAL PRACTICE; COLORECTAL CANCER; COVALENT BOND; DNA METHYLATION; EPIGENETICS; HISTONE MODIFICATION; HUMAN; LABORATORY DIAGNOSIS; LABORATORY TEST; LIFESTYLE; LUNG CANCER; MEDICAL RESEARCH; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSTICS; PATHOPHYSIOLOGY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RARE DISEASE; REVIEW; STRESS;

DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MICRORNAS; NEOPLASMS; PATHOLOGY, MOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 84879374089     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.37     Document Type: Review

References (143)

1. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 22(1), 50-55 (2012).
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 128(4), 683-692 (2007).
3. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2), 178-186 (2009).
4. He L, Hannon GJ. microRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5(7), 522-531 (2004).
5. Hwang HW, Mendell JT. microRNAs in cell proliferation, cell death, and tumori-genesis. Br. J. Cancer 94(6), 776-780 (2006).
6. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9(10), 775-789 (2010).
7. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA 101(9), 2999-3004 (2004).
8. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 318(5858), 1931-1934 (2007).
9. Klopfleisch R, Weiss AT, Gruber AD. Excavation of a buried treasure-DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues. Histol. Histopathol. 26(6), 797-810 (2011).
10. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 403(6765), 41-45 (2000).
11. Talbert PB, Henikoff S. Histone variants-ancient wrap artists of the epigenome. Nat. Rev. Mol. Cell Biol. 11(4), 264-275 (2010).
12. Henikoff S, Furuyama T, Ahmad K. Histone variants, nucleosome assembly and epigenetic inheritance. Trends Genet. 20(7), 320-326 (2004).
13. Ausió J. Histone variants-the structure behind the function. Brief Funct. Genomic Proteomic. 5(3), 228-243 (2006).
14. Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim. Biophys. Acta 1799(10-12), 694-701 (2010).
15. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89-92 (1983).
16. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
17. Flanagan JM, Munoz-Alegre M, Henderson S et al. Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum. Mol. Genet. 18(7), 1332-1342 (2009).
18. Shenker N, Flanagan JM. Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br. J. Cancer 106(2), 248-253 (2012).
19. Jiang MH, Fei J, Lan MS et al. Hypermethylation of hepatic Gck promoter in ageing rats contributes to diabetogenic potential. Diabetologia 51(8), 1525-1533 (2008).
20. Javierre BM, Fernandez AF, Richter J et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 20(2), 170-179 (2010).
21. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 61(8), 3225-3229 (2001).
22. Carmona FJ, Esteller M. DNA methylation in early neoplasia. Cancer Biomark. 9(1-6), 101-111 (2010).
23. Kratz JR, He J, Van Den Eeden SK et al. A practical molecular assay to predict survival in resected nonsquamous, nonsmall-cell lung cancer: development and international validation studies. Lancet 379(9818), 823-832 (2012).
24. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24), 15524-15529 (2002).
25. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103(7), 2257-2261 (2006).
26. Zandberga E, Kozirovskis V, Abols A, Andrejeva D, Purkalne G, Line A. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes. Chromosomes Cancer 52(4), 356-369 (2013).
27. Lawrie CH. microRNA expression in lymphoid malignancies: new hope for diagnosis and therapy? J. Cell. Mol. Med. 12(5 A), 1432-1444 (2008).
28. Jenuwein T, Allis CD. Translating the histone code. Science 293(5532), 1074-1080 (2001).
29. Hake SB, Xiao A, Allis CD. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer 90(4), 761-769 (2004).
30. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10(7), 457-469 (2010).
31. Chervona Y, Costa M. Histone modifications and cancer: biomarkers of prognosis? Am. J. Cancer Res. 2(5), 589-597 (2012).
32. Gray SG. Epigenetic treatment of neurological disease. Epigenomics 3(4), 431-450 (2011).
33. McCord RP, Nazario-Toole A, Zhang H et al. Correlated alterations in genome organization, histone methylation, and DNA-lamin A/C interactions in Hutchinson-Gilford progeria syndrome. Genome Res. 23(2), 260-269 (2013).
34. Lukas J, Lukas C, Bartek J. More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance. Nat. Cell Biol. 13(10), 1161-1169 (2011).
35. Redon CE, Weyemi U, Parekh PR, Huang D, Burrell AS, Bonner WM. g-H2AX and other histone posttranslational modifications in the clinic. Biochim. Biophys. Acta 1819(7), 743-756 (2012).
36. Xu J, Zhang X, Pelayo R et al. Extracellular histones are major mediators of death in sepsis. Nat. Med. 15(11), 1318-1321 (2009).
37. Holdenrieder S, Stieber P. Clinical use of circulating nucleosomes. Crit. Rev. Clin. Lab. Sci. 46(1), 1-24 (2009).
38. Abrams ST, Zhang N, Manson J et al. Circulating histones are mediators of trauma-associated lung injury. Am. J. Respir. Crit. Care Med. 187(2), 160-169 (2013).
39. Tambor V, Kacerovsky M, Lenco J, Bhat G, Menon R. Proteomics and bioinformatics analysis reveal underlying pathways of infection associated histologic chorioamnionitis in pPROM. Placenta 34(2), 155-161 (2013).
40. Herway C, Kanninen T, Witkin SS, Saade G, Fortunato SJ, Menon R. Ethnic disparity in amniotic fluid levels of hyaluronan, histone H2B and superoxide dismutase in spontaneous preterm birth. J. Perinat. Med. 1-6 (2012).
41. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990), 457-463 (2004).
42. Campbell MJ, Turner BM. Altered histone modifications in cancer. Adv. Exp. Med. Biol. 754, 81-107 (2013).
43. Ong TP, Moreno FS, Ross SA. Targeting the epigenome with bioactive food components for cancer prevention. J. Nutrigenet. Nutrigenomics 4(5), 275-292 (2011).
44. Butler JS, Koutelou E, Schibler AC, Dent SY. Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease. Epigenomics 4(2), 163-177 (2012).
45. Biancotto C, Frigè G, Minucci S. Histone modification therapy of cancer. Adv. Genet. 70, 341-386 (2010).
46. Khulan B, Thompson RF, Ye K et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Res. 16(8), 1046-1055 (2006).
47. Levenson VV, Melnikov AA. The MethDet: a technology for biomarker development. Expert Rev. Mol. Diagn. 11(8), 807-812 (2011).
48. García-Giménez JL, Ledesma AM, Esmoris I et al. Histone carbonylation occurs in proliferating cells. Free Radic. Biol. Med. 52(8), 1453-1464 (2012).
49. Gupta R, Nagarajan A, Wajapeyee N. Advances in genome-wide DNA methylation analysis. BioTechniques 49(4), iii-ixi (2010).
50. Bock C. Analysing and interpreting DNA methylation data. Nat. Rev. Genet. 13(10), 705-719 (2012).
51. Koga Y, Pelizzola M, Cheng E et al. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res. 19(8), 1462-1470 (2009).
52. Simmer F, Brinkman AB, Assenov Y et al. Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics 7(12), 1355-1367 (2012).
53. Sandoval J, Heyn H, Moran S et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6(6), 692-702 (2011).
54. Bibikova M, Barnes B, Tsan C et al. High density DNA methylation array with single CpG site resolution. Genomics 98(4), 288-295 (2011).
55. Laird PW. Principles and challenges of genomewide DNA methylation analysis. Nat. Rev. Genet. 11(3), 191-203 (2010).
56. Lister R, O'Malley RC, Tonti-Filippini J et al. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell 133(3), 523-536 (2008).
57. Heyn H, Vidal E, Sayols S et al. Wholegenome bisulfite DNA sequencing of a DNMT3B mutant patient. Epigenetics 7(6), 542-550 (2012).
58. Bock C, Lengauer T. Computational epigenetics. Bioinformatics 24(1), 1-10 (2008).
59. Becker C, Hammerle-Fickinger A, Riedmaier I, Pfaffl MW. mRNA and microRNA quality control for RT-qPCR analysis. Methods 50(4), 237-243 (2010).
60. Dijkstra JR, Mekenkamp LJ, Teerenstra S, De Krijger I, Nagtegaal ID. microRNA expression in formalin-fixed paraffin embedded tissue using real time quantitative PCR: the strengths and pitfalls. J. Cell Mol. Med. 16(4), 683-690 (2012).
61. Kim T, Reitmair A. Non-coding RNAs: functional aspects and diagnostic utility in oncology. Int. J. Mol. Sci. 14(3), 4934-4968 (2013).
62. Kolbert CP, Feddersen RM, Rakhshan F et al. Multi-platform analysis of microRNA expression measurements in RNA from fresh frozen and FFPE tissues. PLoS ONE 8(1), e52517 (2013).
63. Geiss GK, Bumgarner RE, Birditt B et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol. 26(3), 317-325 (2008).
64. Vaz C, Ahmad HM, Sharma P et al. Analysis of microRNA transcriptome by deep sequencing of small RNA libraries of peripheral blood. BMC Genomics 11, 288 (2010).
65. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
66. Rodriguez-Collazo P, Leuba SH, Zlatanova J. Robust methods for purification of histones from cultured mammalian cells with the preservation of their native modifications. Nucleic Acids Res. 37(11), e81 (2009).
67. Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat. Protoc. 2(6), 1445-1457 (2007).
68. Arnaudo AM, Molden RC, Garcia BA. Revealing histone variant induced changes via quantitative proteomics. Crit. Rev. Biochem. Mol. Biol. 46(4), 284-294 (2011).
69. Garcia BA, Shabanowitz J, Hunt DF. Characterization of histones and their post-translational modifications by mass spectrometry. Curr. Opin. Chem. Biol. 11(1), 66-73 (2007).
70. Garcia BA. Mass spectrometric analysis of histone variants and post-translational modifications. Front. Biosci. (Schol. Ed.) 1, 142-153 (2009).
71. Lin S, Garcia BA. Examining histone posttranslational modification patterns by high-resolution mass spectrometry. Meth. Enzymol. 512, 3-28 (2012).
72. Matsuda KM, Chung JY, Hewitt SM. Histoproteomic profiling of formalin-fixed, paraffin-embedded tissue. Expert Rev. Proteomics 7(2), 227-237 (2010).
73. Fowler CB, O'Leary TJ, Mason JT. Protein mass spectrometry applications on FFPE tissue sections. Methods Mol. Biol. 724, 281-295 (2011).
74. Holdenrieder S, Stieber P, Bodenmüller H et al. Nucleosomes in serum as a marker for cell death. Clin. Chem. Lab. Med. 39(7), 596-605 (2001).
75. Holdenrieder S, Nagel D, Schalhorn A et al. Clinical relevance of circulating nucleosomes in cancer. Ann. NY Acad. Sci. 1137, 180-189 (2008).
76. Calin GA, Croce CM. microRNA signatures in human cancers. Nat. Rev. Cancer 6(11), 857-866 (2006).
77. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008).
78. Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37(4), 391-400 (2005).
79. Ponomaryova AA, Rykova EY, Cherdyntseva NV et al. RAR?2 gene methylation level in the circulating DNA from blood of patients with lung cancer. Eur. J. Cancer Prev. 20(6), 453-455 (2011).
80. Kneip C, Schmidt B, Seegebarth A et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J. Thorac. Oncol. 6(10), 1632-1638 (2011).
81. Dietrich D, Kneip C, Raji O et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int. J. Oncol. 40(3), 825-832 (2012).
82. Begum S, Brait M, Dasgupta S et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17(13), 4494-4503 (2011).
83. Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. doi:10.1016/j.canlet.2012.04.018 (2012) (Epub ahead of print).
84. Sanfiorenzo C, Ilie MI, Belaid A et al. Two panels of plasma microRNAs as noninvasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS ONE 8(1), e54596 (2013).
85. Tang D, Shen Y, Wang M et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur. J. Cancer Prev. doi:10.1097/CEJ.0b013e32835f3be9 (2013) (Epub ahead of print).
86. Han HS, Yun J, Lim SN et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinomaassociated malignant pleural effusion. Int. J. Cancer doi:10.1002/ijc.28054 (2013) (Epub ahead of print).
87. Seligson DB, Horvath S, McBrian MA et al. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174(5), 1619-1628 (2009).
88. Van Den Broeck A, Brambilla E, Moro-Sibilot D et al. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin. Cancer Res. 14(22), 7237-7245 (2008).
89. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
90. Warren JD, Xiong W, Bunker AM et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9, 133 (2011).
91. Tóth K, Sipos F, Kalmár A et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left-and right-sided colon cancers. PLoS ONE 7(9), e46000 (2012).
92. deVos T, Tetzner R, Model F et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 55(7), 1337-1346 (2009).
93. Ahlquist DA, Taylor WR, Mahoney DW et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin. Gastroenterol. Hepatol. 10(3), 272-277.e1 (2012).
94. Tänzer M, Balluff B, Distler J et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE 5(2), e9061 (2010).
95. Church TR, Wandell M, Lofton-Day C et al.; for the PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut doi:10.1136/gutjnl-2012-304149 (2013) (Epub ahead of print).
96. Gall TM, Frampton AE, Krell J, Castellano L, Stebbing J, Jiao LR. Blood-based miRNAs as noninvasive diagnostic and surrogative biomarkers in colorectal cancer. Expert Rev. Mol. Diagn. 13(2), 141-145 (2013).
97. Wang S, Xiang J, Li Z et al. A plasma microRNA panel for early detection of colorectal cancer. Int. J. Cancer doi:10.1002/ijc.28136 (2013) (Epub ahead of print).
98. Giraldez MD, Lozano JJ, Ramirez G et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genomewide profiling and validation study. Clin. Gastroenterol. Hepatol. doi:10.1016/j. cgh.2012.12.009 (2012) (Epub ahead of print).
99. Nakazawa T, Kondo T, Ma D et al. Global histone modification of histone H3 in colorectal cancer and its precursor lesions. Hum. Pathol. 43(6), 834-842 (2012).
100. Gezer U, Ustek D, Yörüker EE et al. Characterization of H3K9me3-and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer. Tumour Biol. 34(1), 329-336 (2013).
101. Gezer U, Mert U, Ozgür E, Yörüker EE, Holdenrieder S, Dalay N. Correlation of histone methyl marks with circulating nucleosomes in blood plasma of cancer patients. Oncol. Lett. 3(5), 1095-1098 (2012).
102. Holdenrieder S, Stieber P, Bodenmüller H et al. Nucleosomes in serum of patients with benign and malignant diseases. Int. J. Cancer 95(2), 114-120 (2001).
103. Leszinski G, Gezer U, Siegele B, Stoetzer O, Holdenrieder S. Relevance of histone marks H3K9me3 and H4K20me3 in cancer. Anticancer Res. 32(5), 2199-2205 (2012).
104. Jerónimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93(22), 1747-1752 (2001).
105. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell. Biochem. 91(3), 540-552 (2004).
106. Jerónimo C, Henrique R, Hoque MO et al. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 10(24), 8472-8478 (2004).
107. Baden J, Adams S, Astacio T et al. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J. Urol. 186(5), 2101-2106 (2011).
108. Ellinger J, Haan K, Heukamp LC et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 68(1), 42-49 (2008).
109. Goessl C, Müller M, Heicappell R et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58(3), 335-338 (2001).
110. Van Neste L, Bigley J, Toll A et al. A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. BMC Urol. 12, 16 (2012).
111. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77(5), 1265.e9-1265.16 (2011).
112. Yaman Agaoglu F, Kovancilar M, Dizdar Y et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 32(3), 583-588 (2011).
113. Bryant RJ, Pawlowski T, Catto JW et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 106(4), 768-774 (2012).
114. Seligson DB, Horvath S, Shi T et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435(7046), 1262-1266 (2005).
115. Bianco-Miotto T, Chiam K, Buchanan G et al.; Australian Prostate Cancer BioResource. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol. Biomarkers Prev. 19(10), 2611-2622 (2010).
116. Deligezer U, Yaman F, Darendeliler E et al. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin. Chim. Acta 411(19-20), 1452-1456 (2010).
117. Tsui DW, Lam YM, Lee WS et al. Systematic identification of placental epigenetic signatures for the noninvasive prenatal detection of Edwards syndrome. PLoS ONE 5(11), e15069 (2010).
118. Berdasco M, Esteller M. Genetic syndromes caused by mutations in epigenetic genes. Hum. Genet. 132(4), 359-383 (2013).
119. Salvatore M, Magrelli A, Taruscio D. The role of microRNAs in the biology of rare diseases. Int. J. Mol. Sci. 12(10), 6733-6742 (2011).
120. Keller A, Leidinger P, Lange J et al. Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PLoS ONE 4(10), e7440 (2009).
121. Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS ONE 6(9), e24604 (2011).
122. Schett G, Smole J, Zimmermann C et al. The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 11(11), 704-715 (2002).
123. Kleefstra T, Brunner HG, Amiel J et al. Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am. J. Hum. Genet. 79(2), 370-377 (2006).
124. Porcedda P, Turinetto V, Brusco A et al. A rapid flow cytometry test based on histone H2AX phosphorylation for the sensitive and specific diagnosis of ataxia telangiectasia. Cytometry A 73(6), 508-516 (2008).
125. Rothstein MA, Cai Y, Marchant GE. Ethical implications of epigenetics research. Nat. Rev. Genet. 10(4), 224 (2009).
126. Rothstein MA, Cai Y, Marchant GE. The ghost in our genes: legal and ethical implications of epigenetics. Health Matrix Clevel. 19(1), 1-62 (2009).
127. Cambon-Thomsen A, Ducournau P, Gourraud PA, Pontille D. Biobanks for genomics and genomics for biobanks. Comp. Funct. Genomics 4(6), 628-634 (2003).
128. Botti G, Franco R, Cantile M, Ciliberto G, Ascierto PA. Tumor biobanks in translational medicine. J. Transl. Med. 10, 204 (2012).
129. Lister R, Pelizzola M, Dowen RH et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009).
130. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol. 23(8), 1157-1164 (2010).
131. Yu L, Todd NW, Xing L et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 127(12), 2870-2878 (2010).
132. Shen J, Todd NW, Zhang H et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 91(4), 579-587 (2011).
133. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage nonsmall cell lung cancer. J. Thorac. Oncol. 6(3), 482-488 (2011).
134. Bianchi F, Nicassio F, Marzi M et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol. Med. 3(8), 495-503 (2011).
135. Boeri M, Verri C, Conte D et al. micro-RNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl Acad. Sci. USA 108(9), 3713-3718 (2011).
136. Zheng D, Haddadin S, Wang Y et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int. J. Clin. Exp. Pathol. 4(6), 575-586 (2011).
137. Chen X, Hu Z, Wang W et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int. J. Cancer 130(7), 1620-1628 (2012).
138. Hennessey PT, Sanford T, Choudhary A et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS ONE 7(2), e32307 (2012).
139. Ng EK, Chong WW, Jin H et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58(10), 1375-1381 (2009).
140. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 127(1), 118-126 (2010).
141. Cheng H, Zhang L, Cogdell DE et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 6(3), e17745 (2011).
142. Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J. Cancer Res. Clin. Oncol. 138(10), 1659-1666 (2012).
143. Zandberga E, Kozirovskis V, Ãbols A, Andrejeva D, Purkalne G, Line A. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer. 52(4), 356-369 (2013).